Glypican-3 Expression in Breast Cancer

• Published in: Journal of cancer research and practice Vol. 2; no. 4; pp. 285 - 292
• Main Authors: 蔡青樺(Ching-Hua Tsai), 蘇煒迪(Wei-Ti Su), 沈陳石銘(Shyr-Ming Sheen-Chen), 梁俊隆(Jiun-Lung Liang), 許世偉(Hsien-Wen Hsu), 陳韋廷(Wei-Ting Chen), 黃英彥(Eng-Yen Huang), 黃昭誠(Chao-Cheng Huang), 饒坤銘(Kung-Ming Rau), 唐瑞平(Rei-Ping Tang)
• Format: Journal Article
• Language: English
• Published: 中華民國癌症醫學會 01.12.2015; Elsevier B.V; Wolters Kluwer Medknow Publications
• Subjects: breast cancer; glypican-3; Hematology, Oncology and Palliative Medicine; tissue microarray; 乳癌; glypican-3; breast cancer; 組織微陣列; tissue microarray
• ISSN: 2311-3006; 2311-3006
• DOI: 10.6323/JCRP.2015.2.4.2

Abstract Background The protein Glypican-3 has been found in various types of tumors and has shown promise as a tumor marker. However, there is still very limited information about the role of Glypican-3 in breast cancer. Tissue microarray (TMA) analyzes thousands of specimens in parallel with minimal damage to the origin blocks. The purpose of this study was to ascertain the role of Glypican-3 status in breast cancer using TMA. Materials and Methods Archival tissue specimens from 99 patients with primary invasive breast cancer were analyzed for Glypican-3 expression by immunohistochemical staining with TMA. The results were compared to clinicopathologic data by the use of multivariate analysis. Results TNM stage was significantly related to the overall 5-year survival rate. Nevertheless, Glypican-3 expression has no significant relationship to overall five-year survival. Conclusions Immunohistochemical staining with TMA was convenient and feasible for analyzing Glypican-3 expression status in breast cancer. However, our preliminary results show that Glypican-3 expression had no significant prognostic value in breast cancer.